- Kuijpers Taco W., Tool Anton T. J., van der Bijl Ivo, de Boer Martin, van Houdt Michel, de Cuyper Iris M., Roos Dirk, van Alphen Floris, van Leeuwen Karin, Cambridge Emma L., Arends Mark J., Dougan Gordon, Clare Simon, Ramirez-Solis Ramiro, Pals Steven T., Adams David J., Meijer Alexander B., van den Berg Timo K. Combined immunodeficiency with severe inflammation and allergy caused by ARPC1B deficiency Journal of allergy and clinical immunology 2017;140 (1):273-+ [PubMed]
- van den Berg Timo K., van Bruggen Robin Loss of CD47 Makes Dendritic Cells See Red Immunity 2015;43 (4):622-624 [PubMed]
- Szilagyi Katka, Gazendam Roel P., van Hamme John L., Tool Anton T. J., van Houdt Michel, Vos Wilhelm A. J. W., Verkuijlen Paul, Janssen Hans, Belot Alexandre, Juillard Laurent, Förster-Waldl Elisabeth, Boztug Kaan, Kraal Georg, de Winther Menno P. J., Kuijpers Taco W., van den Berg Timo K. Impaired microbial killing by neutrophils from patients with protein kinase C delta deficiency Journal of allergy and clinical immunology 2015;136 (5):1404-7.e1-10 [PubMed]
- Barclay A. Neil, van den Berg Timo K. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target Annual review of immunology 2014;32:25-50 [PubMed]
- Zhao Xi Wen, van Beek Ellen M., Schornagel Karin, van der Maaden Hans, van Houdt Michel, Otten Marielle A., Finetti Pascal, van Egmond Marjolein, Matozaki Takashi, Kraal Georg, Birnbaum Daniel, van Elsas Andrea, Kuijpers Taco W., Bertucci Francois, van den Berg Timo K. CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction Proceedings of the National Academy of Sciences of the United States of America 2011;108 (45):18342-18347 [PubMed]
Please see my profile on the Sanquin Website:
http://www.sanquin.nl/en/research/principal-investigators/pi-timo-vanden-berg/
Prof. PhD T.K. van den Berg (Phagocyte Biology)
Our group at the Phagocyte Laboratory (Sanquin Research) of the Landsteiner Laboratory is interested in antibody immunotherapy against cancer. The major aim is to improve treatment of cancer patients with therapeutic antibodies in order to reduce the need for non-specific agents, such as chemotherapeutics. We have identified CD47-SIRP interactions as an innate immune checkpoint during antibody therapy in cancer. Work is ongoing to explore the mechanisms of antibody-dependent cancer cell destruction by human innate immune cells and the ways in which this can be further improved. We are also interested in the role of innate immune cells in other diseases, including primary immunodeficiencies. In that context the Phagocyte Laboratory also provides a specialized diagnostic service for phagocyte functional and genetic defects.
Please also see our webpage of the laboratory of Blood Cell Research at Sanquin:
http://www.sanquin.nl/en/research/principal-investigators/pi-timo-vanden-berg/
Postdocs
BEng H.L. Matlung
PhD K. Szilagyi
Others
BEng M. de Boer
BEng J. Geissler
BEng K. Schornagel
PhD A.T.J. Tool
BEng M. van Houdt
K. van Leeuwen
BEng P. Verkuijlen